HeyJaredGwendolyn Wu
- Indexed articles, last 90 days
- 7
- Latest publication
- Sep 29, 2026
- Outlet visibility, for BioPharma Dive
- Top 1M sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Beam sues 2 biotechs, alleging theft of base editing trade secrets (opens the original)
Read excerpt
Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges. Beam Therapeutics is suing the Chinese biotechnology company YolTech Therapeutics and its U.S. partner Serapha Bio, alleging that an experimental treatment licensed between the two companies was developed using trade secrets stolen from Beam. In a complaint filed Sept. 25 with the U.S. District Cou
ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’ (opens the original)
Read excerpt
Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells. A new biotechnology startup called ai3Bio has banked $48 million in an early venture capital round to help pursue medicines for autoimmune diseases, according to a Tuesday announcement. Headquartered in Pittsburgh, Pennsylvania and Watertown, Massachusetts, ai3Bio is built from the parts of two biotechs. One is Corner Therapeuti
Slate, Fulcrum to combine in reverse merger (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Headache drug specialist Slate Medicines said Monday it will combine with struggling biotechnology firm Fulcrum Therapeutics, two months after the latter announced it was seeking strategic alternatives following the discontinuation of its sickle cell drug. Fulcrum spent years developing pociredir, a drug that boosts fetal hemaglobin levels by inhibitin
Cardiac drug developer Braveheart banks more than $382M in IPO (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Braveheart Bio, a cardiac drugmaker, priced Wednesday an initial public offering that brought in $382.5 million in proceeds, adding to a busy year for biotechnology companies going public and raising large sums of cash. It priced more than 21.2 million shares at $18 apiece, exceeding expectations it originally set in a filing last week. The company wil
Judge orders Apple Tree partner to forfeit oversight of venture fund (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A Cayman Islands court has ruled that Seth Harrison, the general partner of biotechnology venture capital firm Apple Tree Partners, should relinquish control of the longtime startup backer. The decision issued Friday could hand the fund's management over to two court-appointed independent directors, Alexander Lawson and Barry Lynch of consulting firm A
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1M sites
For BioPharma Dive, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.